Skip to main content
OpenTrials
Completed

NCT Number: NCT03288675

Stepped Care AiTBS 2 Depression Study (Ghent)

Antidepressant-free unipolar melancholic depressed patients (at least stage 2 treatment-resistant) will be selected by a certified psychiatrist, who will administer (semi-)structured clinical interviews. Because concomitant antidepressant treatment can confound outcome results, all patients will go through a medication washout before entering the study and they will be free from any antidepressant, neuroleptic and mood stabilizer for at least two weeks before entering the treatment protocol. Only habitual benzodiazepine agents will be allowed.

STEP 1: Patients will be treated with in total 20 accelerated intermittent Theta Burst Stimulation (aiTBS) sessions (3000 pulses/session) over the left dorsolateral prefrontal cortex, which will be spread over 4 days. On each stimulation day, a given patient will receive 5 sessions with a between-session delay of 15 minutes. Patients will be randomized to receive either the real aiTBS or sham treatment (first week). However, the sham group will receive real aiTBS treatment with 10 days' time interval. The investigators expect that real aiTBS treatment and not sham will result in a significant and clinical meaningful response.

STEP 2: To optimize treatment and reduce relapse following the iTBS treatment, in a stepped care approach, all patients then continue with cognitive control training (CCT) ten days later. This CCT consists of 20 sessions, spread over 4 weeks. Patients will be randomized to receive either real CCT or a control training. During this follow-up treatment, all patients will be prescribed antidepressant medication (SSRI) again. As iTBS treatment effects are known to decline over time, the investigators expect that combining aiTBS with a follow-up CCT therapy will stabilize the clinical effects over time compared to receiving the iTBS treatment alone.

For baseline comparisons, patients will be closely matched for gender and age with never-depressed, medication-free healthy volunteers. No volunteer will undergo treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University Hospital Ghent

Ghent, East-Flanders, 9000, Belgium

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Antidepressant-free unipolar major depression with melancholic features
  • Not responding to at least two trials with an antidepressant
  • Aged between 18-65 years old

Exclusion criteria

  • Depression with bipolar/psychotic features
  • Dysthymia
  • Severe personality disorders
  • Active substance abuse/dependence within a year prior to inclusion
  • Pregnancy or without effective anticonception for the duration of the trial
  • ECT non-responder
  • No response to more than 9 antidepressants
  • Any neurological condition
  • Any implanted electronic device susceptible for magnetic field radiation (e.g. pacemaker)
  • Any implanted metal device in the head region
  • Current or past history of epilepsy
  • Neurosurgical interventions
  • Known allergic reaction to radiotracers or associated compounds

Healthy volunteers may be accepted as control subjects.

Treatment and study plan

aiTBS

Device

In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.

Other names: accelerated intermittent thetaburst stimulation

CCT

Behavioral

By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.

Other names: cognitive control training

SSRI

Drug

All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).

Other names: selective serotonin reuptake inhibitor

Primary outcomes

  1. Changes in depression severity - clinician-rated

    Time frame: Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    17-item Hamilton Rating Scale for Depression (HRSD)

Secondary outcomes

  1. Changes in depression severity - self-report

    Time frame: Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Beck Depression Inventory (BDI-II)

  2. Changes in suicidal thoughts - clinician-rated

    Time frame: Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Scale for suicidal ideation (SSI)

  3. Changes in melancholic features - clinician-rated

    Time frame: Intake, baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Clinical outcomes in routine evaluation (CORE)

  4. Changes in hopelessness - self-report

    Time frame: Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Beck hopelessness scale (BHS)

  5. Changes in anxiety features - self-report

    Time frame: Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    State/Trait Anxiety Inventory (STAI)

  6. Changes in remission from depression - self-report

    Time frame: Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14), [for the sham group 3 days (+/-D21) and 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Remission from Depression Questionnaire (RDQ)

  7. Changes in ruminative thinking (trait) - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Ruminative Responses Scale (RRS)

  8. Changes in hedonia - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Temporal Experience of Pleasure Scale (TEPS)

  9. Changes in anhedonia - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Snaith-Hamilton Pleasure Scale (SHAPS)

  10. Changes in perceived stress - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Perceived Stress Scale (PSS)

  11. Changes in responses to positive affect - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Responses to Positive Affect Scale (RPA)

  12. Changes in cognitive emotion regulation - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56), 3 & 6 months follow-up

    Cognitive Emotion Regulation Questionnaire (CERQ)

  13. Changes in temperament and character - self-report

    Time frame: Intake, 10 days after aiTBS or sham (+/-D14)

    Temperament and Character Inventory (TCI)

  14. Differences in adverse effects following aiTBS vs. sham - self-report

    Time frame: 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)]

    Adverse effects questionnaire

  15. Changes in regional grey matter volume using structural MRI

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    The analysis will be done using voxel-based morphometry

  16. Changes in regional white matter microstructure and structural connectivity

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    The analysis will be done using diffusion tensor imaging (DTI)

  17. Neuronal safety/ changes in neurometabolite concentrations in left-prefrontal tissues using MRS

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    The analysis will be evaluated using 1H MR spectroscopy

  18. Changes in functional activity connectivity at rest and during tasks in which self-referential social evaluations are presented via headphones in the scanner

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    The analysis will be evaluated using resting state and task fMRI

  19. Changes in state-dependent ruminative thinking due to hearing self-referential social evaluations presented via headphones in the scanner - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    Before entering the scanner, and following each resting state fMRI (i.e. before hearing self-referential social evaluations and after hearing these evaluations), perseverative thinking will be assessed using the perseverative thinking questionnaire (PTQ).

  20. Changes in state-dependent mood due to hearing self-referential social evaluations presented via headphones in the scanner - self-report

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14)

    Before entering the scanner, and following each resting state fMRI (i.e. before hearing self-referential social evaluations and after hearing these evaluations), mood will be assessed using visual analogue scales (VAS).

  21. Changes in the regional 5-HT transporter system

    Time frame: Baseline (D0), 3 days after aiTBS or sham (+/-D7), 10 days after aiTBS or sham (+/-D14)

    C11 DASB PET

  22. Changes in reward processing as measured with EEG /ERP

    Time frame: Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group)

    128 channel EEG during doors gambling task to assess effects on reward processing.

  23. Evaluation of cognitive side-effects following iTBS vs. sham using the CANTAB battery

    Time frame: Baseline (D0), 3 days after aiTBS or sham (+/-D7)

    CANTAB battery administration (i.e. motor screening, delayed matching to sample, rapid visual information processing, one touch stockings of Cambridge, spatial working memory).

  24. Changes in reward processing - behavioral assessment

    Time frame: Baseline (D0), 10 days after aiTBS or sham (+/-D14), [for the sham group 10 days after active aiTBS (+/-D28)], after CCT (+/-D42; for the sham group +/-D56)

    Cambridge Gambling Task (CGT; CANTAB battery)

  25. Changes in working memory - behavioral assessment of near transfer

    Time frame: Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)

    Non-adaptive PASAT (naPASAT)

  26. Changes in state-dependent mood - self-report following naPASAT

    Time frame: Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)

    Visual analogue scales (VAS) administered following completion of the naPASAT

  27. Changes in spatial working memory - behavioral assessment of far transfer

    Time frame: Baseline (D0), 10 days after active aiTBS in both groups (+/-D14 for the active group, +/-D28 for the sham group), after CCT (+/-D42; for the sham group +/-D56)

    Spatial working memory (SWT; CANTAB battery)

  28. Changes in state-dependent mood during CCT vs. control training

    Time frame: Following each of the 20 CCT or control trainings (spread over +/- D15 up to D42 for the active group; spread over +/- D29 up to D56 for the sham group)

    Visual analogue scales (VAS) administered following completion of the CCT (or control training)

  29. Predictive influence of single nucleotide polymorphisms on treatment outcome - genetics using a saliva sample

    Time frame: At baseline (D0)

    SNP analysis

  30. Predictive influence of treatment expectancy on treatment response - self-report

    Time frame: After the first aiTBS or sham session (D1), after the first CCT or control session (+/- D15 for the active group, +/-D29 for the sham group)

    Credibility and Expectancy Questionnaire (CEQ)

Sponsors and collaborators

Lead sponsor

University Hospital, Ghent

Other

Registry information

Official study title

The Effects of Accelerated Intermittent Thetaburst Stimulation Followed by a Cognitive Control Training in Treatment Resistant Unipolar Depressed Patients

Acronym: aiTBS2-Ghent

Important dates

Study start
2017
Primary completion
2023
Study completion
2023
First posted
Sep 20, 2017
Registry last updated
Sep 19, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.